DDInter336 DDInter1435
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Celecoxib {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Celecoxib {u} (Compound) binds {v} (Gene) CA14
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
Celecoxib {u} (Compound) palliates {v} (Disease) osteoarthritis
Celecoxib {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Celecoxib {u} (Compound) downregulates {v} (Gene) TUBB2B
Celecoxib {u} (Compound) causes {v} (Side Effect) Nausea
Celecoxib (Compound) resembles Sulfaphenazole (Compound)
Celecoxib (Compound) resembles Etoricoxib (Compound)
Celecoxib (Compound) binds CA14 (Gene)
Celecoxib (Compound) upregulates ST3GAL5 (Gene)
Celecoxib (Compound) palliates osteoarthritis (Disease)
Celecoxib (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Celecoxib (Compound) downregulates TUBB2B (Gene)
Celecoxib (Compound) causes Nausea (Side Effect)